Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a report issued on Monday,Benzinga reports. The brokerage currently has a $13.00 target price on the stock.

Enlivex Therapeutics Stock Down 15.0 %

Shares of NASDAQ ENLV opened at $1.02 on Monday. The stock has a market capitalization of $21.83 million, a PE ratio of -1.04 and a beta of 0.99. The firm has a fifty day moving average of $1.12 and a 200-day moving average of $1.26. Enlivex Therapeutics has a 52-week low of $0.81 and a 52-week high of $4.59.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings results on Friday, November 29th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.04. Equities research analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in shares of Enlivex Therapeutics in the fourth quarter worth $742,000. Renaissance Technologies LLC increased its holdings in Enlivex Therapeutics by 112.6% in the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after purchasing an additional 84,203 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in Enlivex Therapeutics in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.